The New Directions in Leukaemia Research Conference starts next week and will feature John Rasko and two zinc finger transcription factors called BORIS and CTCF.

Mesenchymal stem cells are being trialled as a potential treatment for graft-versus-host disease, a common complication of bone marrow transplantation.

Apollo aborts mission, investment fund licensed, biotechs move into Phase II trials and NuSep sorts its sperm.

A Phase 1 trial of a transdermal delivery system of pain reliever oxycodone has positive results.

Adelaide company Oncaidia is developing a novel monoclonal antibody it hopes will target cancer by tracking down the La protein and letting loose a firestorm.

Phosphagenics announces Phase II trial of insulin patch.

ANSTO and Siemens will build a $10 million nuclear medicine facility in Sydney.

Sydney-based biopharma Apollo Life Sciences (ASX:AOP) said no significant adverse side-effects were detected in a phase Ib trial of its topical psoriasis cream, developed from human-expressed protein.

A phase Ib clinical trial of Melbourne-based Phosphagenics' (ASX:POH, AIM:PSG) TPM-01 transdermal delivery system has demonstrated that therapeutic levels of morphine in plasma were achieved and maintained for more than 48 hours using the technology.

GroPep (ASX:GRO) has begun to recruit healthy women volunteers into a phase I trial of its infertility drug PV903, targeted to treat recurrent miscarriages caused by an abnormal immune response to the foetus.

Sydney-based biopharma Apollo Life Sciences (ASX:AOP) has commenced its phase Ib clinical trial for a topical psoriasis treatment, developed from human-expressed protein.